Mechanism of therapeutic effectiveness of cefixime against typhoid fever
- PMID:11502513
- PMCID: PMC90676
- DOI: 10.1128/AAC.45.9.2450-2454.2001
Mechanism of therapeutic effectiveness of cefixime against typhoid fever
Abstract
beta-Lactams have been considered ineffective against organisms growing inside mammalian cells because of their poor penetration into cells. However, cefixime has been shown to be clinically effective against typhoid fever. The probable mechanism of therapeutic effectiveness of cefixime against typhoid fever was investigated using Salmonella enterica serovar Typhimurium instead of S. enterica serovar Typhi both in a cellular and in a mouse infection model. Cefixime was able to inhibit the growth of serovar Typhimurium inhabiting monocyte-derived THP-1 cells. Elongation of serovar Typhimurium in THP-1 cells was observed microscopically. Apparent morphological changes of serovar Typhimurium in THP-1 cells were also observed by electron microscopy. The concentration of cefixime inside THP-1 cells was almost half (46 to 48%) of the concentration outside the cells when serovar Typhimurium coexisted in the solution. The length of time after oral dosing (8 mg/kg) that cefixime was present-calculated from levels in serum-at a concentration above the MIC at which 90% of the serovar Typhi organisms inside human cells were inhibited was presumed to be more than 12 h. Cefixime also showed excellent activity in the mouse systemic and oral infection models based on infections caused by serovar Typhimurium. It is concluded that a fair amount of cefixime can enter mammalian cells and inhibit the growth of bacteria inside cells when the bacteria are sensitive enough to cefixime, as are serovars Typhimurium and Typhi.
Figures
, 1 μg/ml;
, 10 μg/ml;
, 100 μg/ml.Similar articles
- Studies on the therapeutic effect of propolis along with standard antibacterial drug in Salmonella enterica serovar Typhimurium infected BALB/c mice.Kalia P, Kumar NR, Harjai K.Kalia P, et al.BMC Complement Altern Med. 2016 Nov 25;16(1):485. doi: 10.1186/s12906-016-1474-5.BMC Complement Altern Med. 2016.PMID:27887651Free PMC article.
- Efficacy of cefixime in the therapy of typhoid fever.Medina Santillán R, Reyes García G, Herrera Benavente I, Mateos García E.Medina Santillán R, et al.Proc West Pharmacol Soc. 2000;43:65-6.Proc West Pharmacol Soc. 2000.PMID:11056958Clinical Trial.No abstract available.
- Differential bacterial survival, replication, and apoptosis-inducing ability of Salmonella serovars within human and murine macrophages.Schwan WR, Huang XZ, Hu L, Kopecko DJ.Schwan WR, et al.Infect Immun. 2000 Mar;68(3):1005-13. doi: 10.1128/IAI.68.3.1005-1013.2000.Infect Immun. 2000.PMID:10678900Free PMC article.
- [Typhoid and paratyphoid fever].Trawinski H, Wendt S, Lippmann N, Heinitz S, von Braun A, Lübbert C.Trawinski H, et al.Z Gastroenterol. 2020 Feb;58(2):160-170. doi: 10.1055/a-1063-1945. Epub 2020 Feb 12.Z Gastroenterol. 2020.PMID:32050286Review.German.
- Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins.Soe GB, Overturf GD.Soe GB, et al.Rev Infect Dis. 1987 Jul-Aug;9(4):719-36. doi: 10.1093/clinids/9.4.719.Rev Infect Dis. 1987.PMID:3125577Review.
Cited by
- In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.Tang HJ, Ko WC, Chen CC, Chen PL, Toh HS, Weng TC, Yu WL, Chiang SR, Chuang YC.Tang HJ, et al.Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.Antimicrob Agents Chemother. 2011.PMID:21402846Free PMC article.
- Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults.Zmora N, Shrestha S, Neuberger A, Paran Y, Tamrakar R, Shrestha A, Madhup SK, Bedi TRS, Koju R, Schwartz E.Zmora N, et al.PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006380. doi: 10.1371/journal.pntd.0006380. eCollection 2018 Apr.PLoS Negl Trop Dis. 2018.PMID:29684022Free PMC article.Clinical Trial.
- What Should We Be Recommending for the Treatment of Enteric Fever?Parry CM, Qamar FN, Rijal S, McCann N, Baker S, Basnyat B.Parry CM, et al.Open Forum Infect Dis. 2023 Jun 2;10(Suppl 1):S26-S31. doi: 10.1093/ofid/ofad179. eCollection 2023 May.Open Forum Infect Dis. 2023.PMID:37274536Free PMC article.
- Studies on the therapeutic effect of propolis along with standard antibacterial drug in Salmonella enterica serovar Typhimurium infected BALB/c mice.Kalia P, Kumar NR, Harjai K.Kalia P, et al.BMC Complement Altern Med. 2016 Nov 25;16(1):485. doi: 10.1186/s12906-016-1474-5.BMC Complement Altern Med. 2016.PMID:27887651Free PMC article.
- An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, Yadav B, Stepniewska K, Campbell JI, Dolecek C, Farrar JJ, Basnyat B.Pandit A, et al.PLoS One. 2007 Jun 27;2(6):e542. doi: 10.1371/journal.pone.0000542.PLoS One. 2007.PMID:17593957Free PMC article.Clinical Trial.
References
- Alam M N, Haq S A, Das K K, Baral P K, Mazid M N, Siddique R U. Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Am J Trop Med Hyg. 1995;53:306–311. - PubMed
- Alsoub H, Uwaydah A K, Mater I, Zebeib M, Elhag K M. A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Br J Clin Pract. 1997;51:8–10. - PubMed
- Bhutta Z A, Khan J A, Molla A M. Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone. Pediatr Infect Dis J. 1994;13:990–994. - PubMed
- Bhutta Z A. A randomized controlled trial of oral cefixime in typhoid fever during childhood: a dose finding study. Proceedings of the 4th International Symposium on Typhoid Fever and Other Salmonellosis, Taiwan. Osaka, Japan: Torre Lazur McCann Inc.; 1999.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical